TAS-102 Monotherapy and Combination Therapy with Bevacizumab for Metastatic Colorectal Cancer
Objective. To evaluate the effectiveness and safety of TAS-102 monotherapy and combination therapy with bevacizumab in the treatment of metastatic colorectal cancer. Methods. The PubMed, Web of Science, MEDLINE, and Cochrane Library databases were searched for the literature on TAS-102 treatment of...
Saved in:
Main Authors: | Cheng-Jiang Liu, Ting Hu, Ping Shao, Wu-Yang Chu, Yu Cao, Feng Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2021-01-01
|
Series: | Gastroenterology Research and Practice |
Online Access: | http://dx.doi.org/10.1155/2021/4014601 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Anticancer effects of PEP06 (TB01) in combination with Trifluridine/Tipiracil (TAS-102) in a xenograft model of human colorectal cancer
by: Ruohong Lin, et al.
Published: (2024-12-01) -
Trifluridine/tipiracil regimen in combination with bevacizumab for metastatic colorectal cancer in the third line: an expert opinion
by: Carmine Pinto, et al.
Published: (2025-01-01) -
Outcomes and Prognostic Factors of Intravitreal Bevacizumab Monotherapy in Zone I Stage 3+ and Aggressive Posterior Retinopathy of Prematurity
by: Simona Delia Nicoară, et al.
Published: (2015-01-01) -
Combination therapy versus monotherapy: retrospective analysis of antibiotic treatment of enterococcal endocarditis
by: Razan Saman, et al.
Published: (2025-01-01) -
Mardin Evlerinde Taş Süsleme
by: İbrahim Halil Karabulut
Published: (2022-10-01)